iCAD’s (ICAD) “Hold” Rating Reiterated at Laidlaw

Laidlaw reissued their hold rating on shares of iCAD (NASDAQ:ICAD) in a research note released on Thursday morning, MarketBeat Ratings reports.

Other research analysts have also issued research reports about the company. BTIG Research lowered iCAD from a “buy” rating to a “neutral” rating in a report on Wednesday. StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research report on Wednesday, March 26th.

iCAD Price Performance

Shares of NASDAQ:ICAD opened at $3.22 on Thursday. The business’s 50-day moving average is $2.36 and its 200-day moving average is $2.12. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78. The company has a market capitalization of $88.12 million, a price-to-earnings ratio of -24.77 and a beta of 1.78.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The firm had revenue of $5.41 million for the quarter, compared to analysts’ expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

Hedge Funds Weigh In On iCAD

A number of hedge funds have recently added to or reduced their stakes in ICAD. Summit Trail Advisors LLC bought a new position in shares of iCAD in the fourth quarter valued at approximately $214,000. First Eagle Investment Management LLC boosted its holdings in iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after acquiring an additional 41,000 shares during the last quarter. Thompson Davis & CO. Inc. bought a new stake in shares of iCAD in the 4th quarter worth $31,000. PKS Advisory Services LLC purchased a new stake in shares of iCAD in the fourth quarter valued at about $53,000. Finally, waypoint wealth counsel lifted its position in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after purchasing an additional 4,400 shares in the last quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.